title: Design and structure-activity relationships of potent and selective inhibitors of blood coagulation factor Xa.
abstract: The discovery of a series of non-peptide factor Xa (FXa) inhibitors incorporating 3-(S)-amino-2-pyrrolidinone as a central template is described. After identifying compound 4, improvements in in vitro potency involved modifications of the liphophilic group and optimizing the angle of presentation of the amidine group to the S1 pocket of FXa. These studies ultimately led to compound RPR120844, a potent inhibitor of FXa (K(i) = 7 nM) which shows selectivity for FXa over trypsin, thrombin, and several fibrinolytic serine proteinases. RPR120844 is an effective anticoagulant in both the rat model of FeCl(2)-induced carotid artery thrombosis and the rabbit model of jugular vein thrombus formation.
authors.affiliation: Departments of Cardiovascular Drug Discovery and New Leads Generation, Rhône-Poulenc Rorer, 500 Arcola Road, Collegeville, Pennsylvania 19426-0107, USA.
authors.forename: W R
authors.initials: WR
authors.lastname: Ewing
authors.forename: M R
authors.initials: MR
authors.lastname: Becker
authors.forename: V E
authors.initials: VE
authors.lastname: Manetta
authors.forename: R S
authors.initials: RS
authors.lastname: Davis
authors.forename: H W
authors.initials: HW
authors.lastname: Pauls
authors.forename: H
authors.initials: H
authors.lastname: Mason
authors.forename: Y M
authors.initials: YM
authors.lastname: Choi-Sledeski
authors.forename: D
authors.initials: D
authors.lastname: Green
authors.forename: D
authors.initials: D
authors.lastname: Cha
authors.forename: A P
authors.initials: AP
authors.lastname: Spada
authors.forename: D L
authors.initials: DL
authors.lastname: Cheney
authors.forename: J S
authors.initials: JS
authors.lastname: Mason
authors.forename: S
authors.initials: S
authors.lastname: Maignan
authors.forename: J P
authors.initials: JP
authors.lastname: Guilloteau
authors.forename: K
authors.initials: K
authors.lastname: Brown
authors.forename: D
authors.initials: D
authors.lastname: Colussi
authors.forename: R
authors.initials: R
authors.lastname: Bentley
authors.forename: J
authors.initials: J
authors.lastname: Bostwick
authors.forename: C J
authors.initials: CJ
authors.lastname: Kasiewski
authors.forename: S R
authors.initials: SR
authors.lastname: Morgan
authors.forename: R J
authors.initials: RJ
authors.lastname: Leadley
authors.forename: C T
authors.initials: CT
authors.lastname: Dunwiddie
authors.forename: M H
authors.initials: MH
authors.lastname: Perrone
authors.forename: V
authors.initials: V
authors.lastname: Chu
mesh_terms: D000818:Animals; D000925:Anticoagulants / Q000138:chemical synthesis* / Q000494:pharmacology; D018360:Crystallography, X-Ray; D065427:Factor Xa Inhibitors; D006801:Humans; D008958:Models, Molecular; D015394:Molecular Structure; D011760:Pyrrolidinones / Q000138:chemical synthesis* / Q000494:pharmacology; D011817:Rabbits; D051381:Rats; D015842:Serine Proteinase Inhibitors / Q000138:chemical synthesis / Q000494:pharmacology; D013237:Stereoisomerism; D013329:Structure-Activity Relationship; D013449:Sulfonamides / Q000138:chemical synthesis* / Q000494:pharmacology; D013876:Thiophenes / Q000138:chemical synthesis* / Q000494:pharmacology; D013927:Thrombosis / Q000188:drug therapy
chemical_list: D000925:Anticoagulants; D065427:Factor Xa Inhibitors; D011760:Pyrrolidinones; C118977:RPR 120844; D015842:Serine Proteinase Inhibitors; D013449:Sulfonamides; D013876:Thiophenes